Home
BMY
BMY News

Latest Bristol-Myers Squibb Company (BMY) News on June 21, 2025

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

Zacks

2 days ago

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

Zacks

2 days ago

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks

StockStory

2 days ago

Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks

Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends

Simply Wall St.

2 days ago

Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends

Trump administration weighs crackdown on pharma ads, Bloomberg says

TipRanks

3 days ago

Trump administration weighs crackdown on pharma ads, Bloomberg says

Bristol Myers Squibb Announces Dividend

Business Wire

3 days ago

Bristol Myers Squibb Announces Dividend

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

Zacks

3 days ago

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

MT Newswires

3 days ago

Market Chatter: Trump Administration to Consider Pharma Advertising Crackdown

Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress

Insider Monkey

4 days ago

Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress

Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note

Zacks

4 days ago

Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note

MT Newswires

5 days ago

Bristol-Myers Squibb Says Breyanzi Shows 'Lasting' Response in Marginal Zone Lymphoma Trial

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

Business Wire

5 days ago

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

2 Beaten-Down Dividend Stocks to Buy Right Now

Motley Fool

5 days ago

2 Beaten-Down Dividend Stocks to Buy Right Now

Senators to propose ban on drug ads to consumers, WSJ reports

TipRanks

7 days ago

Senators to propose ban on drug ads to consumers, WSJ reports

Tariffs Create Most Patriotic Earnings Season Yet as US Firms Pander to Trump

Bloomberg

8 days ago

Tariffs Create Most Patriotic Earnings Season Yet as US Firms Pander to Trump

BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

Zacks

8 days ago

BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

BMY Reports Positive Data on Sotyktu From Arthritis Study

Zacks

9 days ago

BMY Reports Positive Data on Sotyktu From Arthritis Study

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Business Wire

9 days ago

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Business Wire

9 days ago

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu

Simply Wall St.

9 days ago

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu

MT Newswires

9 days ago

Bristol-Myers Squibb's Sotyktu to Treat Psoriatic Arthritis Meets Primary Goal

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

TipRanks

9 days ago

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

10 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Zacks

10 days ago

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal

BioPharma Dive

10 days ago

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Business Wire

10 days ago

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

MT Newswires

10 days ago

Bristol-Myers Squibb Unit Enters License for Prostate Cancer Drug Candidate Rights

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

GlobeNewswire

10 days ago

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider

Zacks

11 days ago

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider

Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks

12 days ago

Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?

Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space

Zacks

12 days ago

Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space

3 Stocks With Mouthwatering Dividends You Can Buy Right Now

Motley Fool

13 days ago

3 Stocks With Mouthwatering Dividends You Can Buy Right Now

Patents and economies of scale support Pfizer's wide moat

GuruFocus.com

14 days ago

Patents and economies of scale support Pfizer's wide moat

Markey Researchers Awarded $6.8 Million To Help Others Replicate Kentucky's Lung Cancer Screening Success

ACCESS Newswire

15 days ago

Markey Researchers Awarded $6.8 Million To Help Others Replicate Kentucky's Lung Cancer Screening Success

Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?

Insider Monkey

15 days ago

Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?

BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?

Zacks

15 days ago

BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?

Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers

StockStory

15 days ago

Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Zacks

15 days ago

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About

StockStory

16 days ago

1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About

Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment

Simply Wall St.

17 days ago

Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment

Bristol Myers Collaborates With BNTX for Oncology Candidate

Zacks

17 days ago

Bristol Myers Collaborates With BNTX for Oncology Candidate

Trump’s Tax Bill Is Testing the Dollar. This Red Flag Matters More.

Barrons.com

18 days ago

Trump’s Tax Bill Is Testing the Dollar. This Red Flag Matters More.

Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up

The Daily Upside

18 days ago

Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up

Why BioNTech SE (BNTX) Skyrocketed On Monday

Insider Monkey

18 days ago

Why BioNTech SE (BNTX) Skyrocketed On Monday

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

Zacks

18 days ago

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

BioNTech Gains 20% On $11.1 Billion Bristol Deal

GuruFocus.com

18 days ago

BioNTech Gains 20% On $11.1 Billion Bristol Deal

Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal

Bloomberg

19 days ago

Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal

Investing.com

19 days ago

BioNTech soars 15% on cancer drug deal with Bristol Myers

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

The Wall Street Journal

19 days ago

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

MT Newswires

19 days ago

BioNTech, Bristol Myers Squibb to Co-Develop Bispecific Cancer Treatment

Investing.com

19 days ago

BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

Business Wire

19 days ago

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

Bristol Myers allies with BioNTech on bispecific cancer drug

BioPharma Dive

19 days ago

Bristol Myers allies with BioNTech on bispecific cancer drug

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)

StockStory

19 days ago

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)

A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE

Simply Wall St.

21 days ago

A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE

Morningstar Research

21 days ago

Analyst Report: Bristol-Myers Squibb Company

MT Newswires

22 days ago

Meitheal Launches Generic Form of Bristol-Myers Squibb's Abraxane in US

Bristol CEO: Pharma Tariffs Must Not Jeopardize Medicine Supplies

The Wall Street Journal

22 days ago

Bristol CEO: Pharma Tariffs Must Not Jeopardize Medicine Supplies

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

Zacks

22 days ago

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?

Zacks

23 days ago

Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?

EC approves BMS’ nivolumab SC formulation for solid tumours

Pharmaceutical Technology

23 days ago

EC approves BMS’ nivolumab SC formulation for solid tumours

1 S&P 500 Stock for Long-Term Investors and 2 to Brush Off

StockStory

23 days ago

1 S&P 500 Stock for Long-Term Investors and 2 to Brush Off

MT Newswires

23 days ago

Update: Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

24 days ago

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

MT Newswires

24 days ago

Bristol Myers Squibb Gets EC Approval for Subcutaneous Formulation of Opdivo

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Business Wire

24 days ago

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Business Wire

24 days ago

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

MT Newswires

24 days ago

Berenberg Adjusts Price Target on Bristol-Myers Squibb to $55 From $60, Maintains Hold Rating

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

Zacks

24 days ago

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?

Zacks

a month ago

Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?

Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting

Simply Wall St.

a month ago

Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Zacks

a month ago

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

With 81% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing

Simply Wall St.

a month ago

With 81% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Business Wire

a month ago

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

StockStory

a month ago

1 Safe-and-Steady Stock to Own for Decades and 2 to Think Twice About

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

StockStory

a month ago

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

Business Wire

a month ago

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

Here's How You Can Earn $100 In Passive Income By Investing In Bristol-Myers Squibb Stock

Benzinga

a month ago

Here's How You Can Earn $100 In Passive Income By Investing In Bristol-Myers Squibb Stock

Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?

Zacks

a month ago

Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?

EC approves BMS’ perioperative Opdivo and chemo for NSCLC

Pharmaceutical Technology

a month ago

EC approves BMS’ perioperative Opdivo and chemo for NSCLC

Judge shuts down drugmakers’ 340B rebate plans, for now

Healthcare Dive

a month ago

Judge shuts down drugmakers’ 340B rebate plans, for now

Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom”

Insider Monkey

a month ago

Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom”

Bristol-Myers Squibb (NYSE:BMY) Gains EC Approval for Opdivo in Lung Cancer Treatment

Simply Wall St.

a month ago

Bristol-Myers Squibb (NYSE:BMY) Gains EC Approval for Opdivo in Lung Cancer Treatment

MT Newswires

a month ago

Bristol-Myers Squibb Receives European Approval for Opdivo Regimen to Treat Lung Cancer

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

Business Wire

a month ago

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

Jefferies not seeing significant impact to Merck, Bristol from draft guidance

TipRanks

a month ago

Jefferies not seeing significant impact to Merck, Bristol from draft guidance

What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks

Motley Fool

a month ago

What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks

Morningstar Research

a month ago

Analyst Report: Bristol-Myers Squibb Company

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Zacks

a month ago

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Why Bristol-Myers Squibb Company (BMY) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

Insider Monkey

a month ago

Why Bristol-Myers Squibb Company (BMY) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

Investor's Business Daily

a month ago

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

Drugmakers Avoid Worst-Case Pricing Scenario for Now

The Wall Street Journal

a month ago

Drugmakers Avoid Worst-Case Pricing Scenario for Now

Morningstar Research

a month ago

Analyst Report: Bristol-Myers Squibb Company

Drug wars: Wall Street says big questions remain about impact of Trump's new pricing order

Yahoo Finance

a month ago

Drug wars: Wall Street says big questions remain about impact of Trump's new pricing order

MT Newswires

a month ago

Bristol-Myers Squibb, Sanofi Enter $700 Million Settlement With Hawaii in Plavix Lawsuit

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Bloomberg

a month ago

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

BMY Q1 Earnings Call: Growth Portfolio Offsets Declines, Guidance Raised Amid Pipeline Advancements

StockStory

a month ago

BMY Q1 Earnings Call: Growth Portfolio Offsets Declines, Guidance Raised Amid Pipeline Advancements

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

Bloomberg

a month ago

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

Bristol-Myers Squibb Company (BMY): One of the Best High-Yield Dividend Stocks for 2025 and Beyond

Insider Monkey

a month ago

Bristol-Myers Squibb Company (BMY): One of the Best High-Yield Dividend Stocks for 2025 and Beyond

Associated Press Finance

a month ago

Drug companies to pay Hawaii $700 million to settle Plavix blood thinner lawsuit

Share on Social Networks: